News

Taiwan News18h
Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced poster presentations at the ...
Vietnam Investment Review1d
Innovent Showcases Breakthrough Preclinical Data on Novel Antibodies at AACR 2025
IBI3014 is a bispecific ADC targeting TROP2 and PD-L1. Its dual mechanism integrates TROP2-directed tumor killing with PD-L1 ...
Taiwan News1d
2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs
IBI3014 is a bispecific ADC targeting TROP2 and PD-L1. Its dual mechanism integrates TROP2-directed tumor killing with PD-L1 immune checkpoint blockade, enhancing immunogenic cell death and T cell ...
Le Lézard4d
Element Biosciences Accelerates Rollout of Direct in Sample Sequencing for the AVITI24tm Intelligent Multiomics System to Meet Growing Demand
Element Biosciences, Inc., a company democratizing access to advanced life science solutions, today announced the accelerated rollout and availability of direct in sample sequencing on AVITI24, the ...
Element Biosciences Accelerates Rollout of Direct in Sample Sequencing for the AVITI24™ Intelligent Multiomics System to Meet Growing Demand
Element Biosciences to present four abstracts at the AACR 2025 annual meeting highlighting research from AVITI24 and the ...